These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37428848)

  • 21. Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes.
    Fan C; Cohen AA; Park M; Hung AF; Keeffe JR; Gnanapragasam PNP; Lee YE; Gao H; Kakutani LM; Wu Z; Kleanthous H; Malecek KE; Williams JC; Bjorkman PJ
    Immunity; 2022 Dec; 55(12):2419-2435.e10. PubMed ID: 36370711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural insights into the rational design of a nanobody that binds with high affinity to the SARS-CoV-2 spike variant.
    Yamaguchi K; Anzai I; Maeda R; Moriguchi M; Watanabe T; Imura A; Takaori-Kondo A; Inoue T
    J Biochem; 2023 Feb; 173(2):115-127. PubMed ID: 36413757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
    Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W
    Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.
    Sui J; Deming M; Rockx B; Liddington RC; Zhu QK; Baric RS; Marasco WA
    J Virol; 2014 Dec; 88(23):13769-80. PubMed ID: 25231316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SARS-CoV-2 evolves to reduce but not abolish neutralizing action.
    Zhang Y; Ndzouboukou JB; Lin X; Hou H; Wang F; Yuan L; Gan M; Yao Z; Fu H; Cao J; Fan X
    J Med Virol; 2023 Jan; 95(1):e28207. PubMed ID: 36217880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant.
    Yuan M; Zhu Y; Liu G; Wang Y; Wang G; Zhang G; Ye L; Qian Z; Liu P
    One Health Adv; 2023; 1(1):12. PubMed ID: 37521533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanobodies Protecting From Lethal SARS-CoV-2 Infection Target Receptor Binding Epitopes Preserved in Virus Variants Other Than Omicron.
    Casasnovas JM; Margolles Y; Noriega MA; Guzmán M; Arranz R; Melero R; Casanova M; Corbera JA; Jiménez-de-Oya N; Gastaminza P; Garaigorta U; Saiz JC; Martín-Acebes MÁ; Fernández LÁ
    Front Immunol; 2022; 13():863831. PubMed ID: 35547740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
    Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
    mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.
    Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain.
    Wheatley AK; Pymm P; Esterbauer R; Dietrich MH; Lee WS; Drew D; Kelly HG; Chan LJ; Mordant FL; Black KA; Adair A; Tan HX; Juno JA; Wragg KM; Amarasena T; Lopez E; Selva KJ; Haycroft ER; Cooney JP; Venugopal H; Tan LL; O Neill MT; Allison CC; Cromer D; Davenport MP; Bowen RA; Chung AW; Pellegrini M; Liddament MT; Glukhova A; Subbarao K; Kent SJ; Tham WH
    Cell Rep; 2021 Oct; 37(2):109822. PubMed ID: 34610292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resilience of Spike-Specific Immunity Induced by COVID-19 Vaccines against SARS-CoV-2 Variants.
    Ballesteros-Sanabria L; Pelaez-Prestel HF; Ras-Carmona A; Reche PA
    Biomedicines; 2022 Apr; 10(5):. PubMed ID: 35625733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A broadly reactive antibody targeting the N-terminal domain of SARS-CoV-2 spike confers Fc-mediated protection.
    Adams LJ; VanBlargan LA; Liu Z; Gilchuk P; Zhao H; Chen RE; Raju S; Chong Z; Whitener BM; Shrihari S; Jethva PN; Gross ML; Crowe JE; Whelan SPJ; Diamond MS; Fremont DH
    Cell Rep Med; 2023 Dec; 4(12):101305. PubMed ID: 38039973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Spike-destructing human antibody effectively neutralizes Omicron-included SARS-CoV-2 variants with therapeutic efficacy.
    Meng L; Zha J; Zhou B; Cao L; Jiang C; Zhu Y; Li T; Lu L; Zhang J; Yang H; Feng J; Gu Z; Tang H; Jiang L; Li D; Lavillette D; Zhang X
    PLoS Pathog; 2023 Jan; 19(1):e1011085. PubMed ID: 36706160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode.
    Zhao D; Liu L; Liu X; Zhang J; Yin Y; Luan L; Jiang D; Yang X; Li L; Xiong H; Xing D; Zheng Q; Xia N; Tao Y; Li S; Huang H
    J Nanobiotechnology; 2022 Sep; 20(1):411. PubMed ID: 36109732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular Basis of Mink ACE2 Binding to SARS-CoV-2 and Its Mink-Derived Variants.
    Su C; He J; Han P; Bai B; Li D; Cao J; Tian M; Hu Y; Zheng A; Niu S; Chen Q; Rong X; Zhang Y; Li W; Qi J; Zhao X; Yang M; Wang Q; Gao GF
    J Virol; 2022 Sep; 96(17):e0081422. PubMed ID: 36000849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of key mutations responsible for the enhancement of receptor-binding affinity and immune escape of SARS-CoV-2 Omicron variant.
    Wang WB; Ma YB; Lei ZH; Zhang XF; Li J; Li SS; Dong ZY; Liang Y; Li QM; Su JG
    J Mol Graph Model; 2023 Nov; 124():108540. PubMed ID: 37352723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional Analysis of Spike from SARS-CoV-2 Variants Reveals the Role of Distinct Mutations in Neutralization Potential and Viral Infectivity.
    Kuzmina A; Wattad S; Engel S; Rosenberg E; Taube R
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of SARS-CoV-2 Escape Mutants to a Pair of Neutralizing Antibodies Targeting the RBD and the NTD.
    Peter AS; Grüner E; Socher E; Fraedrich K; Richel E; Mueller-Schmucker S; Cordsmeier A; Ensser A; Sticht H; Überla K
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies.
    Shah M; Woo HG
    Front Immunol; 2021; 12():830527. PubMed ID: 35140714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The molecular basis of the neutralization breadth of the RBD-specific antibody CoV11.
    Tolbert WD; Chen Y; Sun L; Benlarbi M; Ding S; Manickam R; Pangaro E; Nguyen DN; Gottumukkala S; Côté M; Gonzalez FJ; Finzi A; Tehrani ZR; Sajadi MM; Pazgier M
    Front Immunol; 2023; 14():1178355. PubMed ID: 37334379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.